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1. Introduction 
The highly pathogenic Nipah virus (NiV) emerged in epidemics in Malaysia in 1998. 
Regular outbreaks occur since then in Bangladesh and India with the high mortality rate 
reaching up to 90%. During the first emergence in Malaysia, the only way to contain the 
outbreak was culling of more than one million pigs leading to major economic issues, 
estimated at over US$ 100 million (Lee, 2007). Thus, NiV is considered as a potential agent of 
bioterrorism and is designated as priority pathogens in the National Institute of Allergy and 
Infectious Diseases (NAID) Biodefense Research Agenda. Neither treatment nor vaccines are 
available against NiV infection, limiting thus experimentation with live virus to Biosafety 
level 4 (BSL4) laboratories, which require the highest level of precaution. 
Nipah virus infection is often associated to the development of the wide spread vasculitis 
but molecular basis of its pathogenicity is still largely unknown. To gain insight in the 
pathogenesis of this highly lethal virus we have performed analysis of virus-induced early 
transcriptome changes in primary endothelial cells, which are first targets of Nipah infection 
in humans. 
1.1 The virus 
Together with the closely related Hendra virus (HeV) that appeared in Australia in 1994, 
NiV has been classified in the new genus called Henipavirus, in the Paramyxoviridae 
family. Placed in the order of the Mononegavirales, this family has nonsegmented single 
stranded negative-sense RNA genome (Lamb & Parks 2007). Henipavirus encodes 6 
structural proteins: the nucleocapsid N, phosphoprotein P, the matrix protein M, fusion F, 
attachment G, and the large polymerase L. The P gene also codes for non-structural protein 
through two different strategies. First, by mRNA editing, pseudotemplated guanosine 
residues could be inserted causing a frame shift of either 1 or 2 nucleotides leading to the 
production of the proteins V and W. The C protein is produced through the initiation of 
translation of P mRNA at an alternative start codon 20 nucleotides downstream in the +1 
ORF (Wang et al., 2001). Because of its short length, the C protein can be produced through 
P, V and W mRNAs (Fontana et al., 2008). 
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Numerous studies have demonstrated that the natural hosts of NiV are flying foxes in the 
genera Pteropus and Eidolon in South-East Asia as well as in Madagascar (Iehlé et al., 2007) 
and Ghana (Drexler et al., 2009). The emergence of NiV as zoonosis could be due to the fact 
that large areas of South East Asia have recently been subject to deforestation. 
Consequently, breeding territories of giant bats have been found in close proximity to 
people habitation, which has facilitated contact with domesticated animals as well as with 
humans. Since its emergence in Malaysia in 1998, NiV was shown to be different from the 
other members of its family by its capacity to cause the most important zoonosis ever 
observed within Paramyxoviridae. Indeed, during this first outbreak, the virus infected 
humans, pigs, cats, dogs and horses (Maisner et al., 2009). Among infected people, about 
90% were working in pig farms. Serological analysis revealed that pigs were responsible for 
the transmission of Nipah virus to humans. Therefore, in order to contain this first 
occurrence, more than 1 million pigs were culled. Although it seems that Nipah outbreaks 
have been stopped in Malaysia, the virus continues to cause regular outbreaks from 2001 up 
to nowdays in India and Bangladesh. However, pigs were not involved in those outbreaks, 
and virus seemed to be transmitted directly form its natural reservoir fruit bats, to humans. 
Fruit bats from Malaysia, Cambodia, Bangladesh and Thailand were tested and the studies 
revealed the existence of new strains of NiV (Halpin & Mungall 2007). Even the virus can 
pass via an intermediate host like pigs, viral transmission occurs during last few years from 
bats to humans through palm juice (Luby et al., 2006) and has been responsible for 
reappearance of NiV in 2010 (17 deaths) and 2011 (35 deaths) increasing the total number of 
NiV outbreaks to 13 since its first appearance (Nahar et al., 2010)(Salah et al., 2011). Finally, 
human to human transmission has been documented in more than half of the outbreaks 
(Gurley et al., 2007, Luby et al., 2009). 
1.3 NiV tropism 
NiV can naturally infect a large panel of mammals suggesting the high conservation of its 
receptor among them (Eaton et al., 2006). In addition, the glycoproteins G of the 
Henipavirus show a tropism for a number of different cell types including neural, 
endothelial, muscular and epithelial cells (Bossart et al., 2002). Ephrin B2 (EFN B2) has been 
demonstrated as the receptor for both NiV and HeV. Indeed, this highly conserved protein 
is expressed at the surface of all permissive cell lines. Moreover, the transfection of cells with 
the gene coding for EFN B2 makes them permissive to the infection (Negrete et al., 2005). 
EFN B2 is essential to vasculogenesis and neuronal development. This transmembrane 
protein of 330 aa is expressed by numerous cells, but more particularly at the surface of 
epithelial, endothelial, smooth muscles and neuronal cells, that show the highest level of 
viral antigens during infection in patients (Lee, 2007). Finally, despite the high affinity of 
NiV for EFN B2, its expression at the surface of cells is not always sufficient for the virus 
entry, suggesting the existence of an additional receptor or intracellular factor necessary for 
viral replication (Yoneda et al., 2006).   
The second entry receptor for NiV and HeV has been identified: Ephrin B3 (EFN B3), with 
the affinity for NiV 10 times lower than EFN B2 (Negrete et al., 2006). EFN B3 is a 
transmembrane protein of 340 aa. At the position 121 and 122 of EFN B3 and B2, 2aa appear 
essential for the virus entry. In contrast to EFN B2, EFN B3 is more expressed at the level of 
the brainstem, which could be linked with the severity of the neuron dysfunctions during 
the NiV encephalitis (Negrete et al., 2007). 
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1.4 The pathology in humans 
After incubation period which varies from 4 to 60 days, NiV infection starts similarly to flu. 
In the large majority of the cases patients present fever, whereas 2/3 of them develop 
headache, leading frequently to severe acute encephalitis with loss of consciousness. Some 
of patients develop in addition respiratory symptoms. Death occurs in 40 to 90% within an 
average time of 10 days post fever, due to the severity of the cerebral damages (Lee, 2007). 
The pathology is characterized by a systemic vasculitis with syncytia formation of 
microvascular endothelial and epithelial cells (Fig. 1). Perivascular cuffing is generally 
observed. Despite the fact that the virus infects all organs, the microvascularization of 
central nervous system shows the most severe damages.  
 
 
Fig. 1. Photos of hematoxylin staining of cerebral cortex of patients infected with NiV during 
the first outbreak in Malaysia, showing widespread vasculitis (personal data) 
Patients show wide lymphoid necrosis associated to giant multinucleated cells that could be 
related to the presence of the NiV in this tissue. Virus may propagate initially within the 
lymphoid tissue, leading to the infection of the endothelial cells, recognized as the first 
primary targets of NiV. Those cells allow the second cycle of replication of the virus and the 
viremia. 
NiV infection is characterized by the formation of syncytia leading to the endothelial 
damages, which are thought to be the cause of thrombosis, inflammation, ischemia and 
finally necrosis. Resulting vascular infarctions and infiltrates lead to extravascular infection 
and parenchymatous invasion. The invasion of the central nervous system is generally 
followed by the lethal encephalitis. 
Patients who have survived the NiV infection showed severe weakness sometime persisting 
for several months, and often complicated by neurological and/or motor dysfunctions 
(Sejvar et al., 2007). Those symptoms appear as a direct consequence of the acute 
encephalitis. Indeed, those patients develop atrophy of the cerebellum, brainstem lesions, 
cortical nervous transmission abnormalities and are particularly affected in the white matter 
(Ng et al., 2004). In Malaysia, about 7,5% of patients who survived the encephalitis had 
relapsed during the year following their infection without any reexposure to virus. In 
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addition, NiV can cause apparently asymptomatic infection leading to the late onset 
encephalitis several months to a year after infection (Tan et al., 2002). This fact suggests that 
the virus can infect more people than those showing clinical symptoms and may stay in 
latent stage until reactivation under the influence of some still unknown factors. 
1.5 Vaccines and treatments 
Several studies have been focused on the development of anti-NiV vaccines. The first study 
has shown that hamsters, vaccinated with vaccinia virus expressing either NiV F or G, were 
completely protected against NiV. Moreover, this group demonstrated that the naïve 
animals were also protected by passive transfer of hyperimmune serum prior to challenge 
(Guillaume et al., 2004). An important advance was next the development of a recombinant 
vaccine protecting pigs against NiV challenge (Weingartl et al., 2006). The Canarypox virus 
expressing NiV glycoproteins was shown to be very efficient in pigs and may have a real 
socio-economic interest in the case of new NiV outbreaks. Recently, one group showed 
induction of neutralizing antibodies to Henipavirus using an Alphavirus based vaccine 
(Defang et al., 2010). However, the study has been performed in mice which are not 
sensitive to NiV infection (Wong et al., 2003), preventing them from testing the efficiency of 
the vaccination. 
Monoclonal antibodies against NiV glycoproteins were shown to protect 50% of infected 
hamsters even when treatments started 24 h post infection (Guillaume et al., 2006) and anti-
NiV F monoclonal antibodies protected hamsters against Hendra virus infection as well 
(Guillaume et al., 2009). In addition, neutralizing human monoclonal antibody protected 
ferrets from NiV infection, when given 10 h after oronasal administration of the virus 
(Bossart et al., 2009).  
Treatment of NiV infection was tested using some of known anti-viral chemicals: ribavirin 
(Chong et al., 2001), chloroquine (Pallister et al., 2009), gliotoxin, gentian violet and brilliant 
green (Aljofan et al., 2009). Most of those products showed an effect either in vitro or in vivo 
but with too low efficiency to consider them as a good treatment for infected patients, even 
if they were used combined (Freiberg et al., 2010). Finally, anti-fusion peptides were 
designed that specifically target the entry of Henipavirus (Porotto et al., 2010). To improve 
the efficiency of this potential treatment, this group has added a cholesterol tag, highly 
increasing the anti-viral efficiency and allowing peptides to reach brain and limit viral entry 
into cerebral cells, giving thus very promising results both in vitro and in vivo in hamsters 
(Porotto et al., 2010). This new anti-viral approach needs now to be tested in a primate 
model to consider its potential utilization in humans. 
2. Global gene expression analysis of NiV infected endothelial cells, using 
microarrays 
Profound changes are occurring in host cells during viral infections. These pathogen-
induced changes are often accompanied by marked changes in gene expression and could 
be followed through the analysis of the specific RNA fingerprint related to each virus (Glass 
et al., 2003), (Jenner et al., 2005). For this purpose, microarrays present the essential tool to 
study global changes in gene expression and better understand which cellular mechanisms 
are modulated during the viral replication cycle. The aim of this study was to obtain a global 
overview of NiV effect on endothelial cells, in order to open new perspectives In treatment 
of this lethal infection. 
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Very little is known on pathogenesis of NiV infection. To obtain the global insight in 
different host cell changes during the infection, we have performed gene expression analysis 
using microarrays. In vivo, primary targets of this virus are endothelial cells, smooth muscles 
and neurons. The infection of microvascular endothelial cells leads to a generalized 
vasculitis, which is the common symptom diagnosed among all infected animals and 
humans. This vasculitis usually induces the acute encephalitis that is observed in severe NiV 
infection. Therefore, primary human endothelial cells were chosen as the most relevant host 
cell type to analyze the effect of NiV infection on the host cell gene expression. 
 
 
Fig. 2. HUVEC infected with the NiV recombinant strain expressing EGFP (MOI=1) for 24h 
and presenting a large syncytia, observed under the fluorescent microscope. 
2.1 HUVEC culture and NiV infection 
We have, thus, analyzed the effect of NiV infection in primary human umbilical vein 
endothelial cells (HUVEC). These cells are highly permissive to NiV infection and develop 
large syncytia rapidly after infection, as shown when recombinant NiV expressing the 
fluorescent green protein EGFP (Yoneda et al., 2006) is used for infection (Fig. 2). Primary 
HUVEC cells were isolated from umbilical cords of 6 donors (Jaffe et al., 1973). Cells were 
then transferred in a 75ml flask, precoated with gelatin 0,2% in PBS for 30 min and washed. 
The following day, cells were trypsinated to eliminate any dead or residual blood cells, and 
pooled by 2 sets of 3 donors and put in new flasks in order to cover 50% of the surface. After 
one week of culture, cells were submitted to 16 hours of serum privation just before their 
infection. 
The infection was performed using wild type NiV (isolate UM-MC1, Gene accession 
N°AY029767) at MOI 1, in 2 sets of 3 different donors, in BSL4 Laboratory Jean Mérieux in 
Lyon, France.  
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2.2 Microarray experiments 
Early changes associated to initial stages of NiV infection were analyzed by microarray 
approach (Fig. 3). Total RNAs were extracted from infected cells at 8h post infection and 
from uninfected cells (mock) cultured in the same conditions. Quality of total RNA was 
checked on Agilent bioanalyzer 2100. Amplified and biotin-labeled RNAs were obtained 
from 2μg of total RNA, using the Ambion message Amp kit version II. Different quantities 
of positive RNA controls (spikes) were added during the first step of reverse transcription of 
total RNAs. Spikes correspond to 6 bacterial RNAs used to control sensitivity, quality of 
hybridization and data normalization. Hybridization was performed on Codelink human 
whole genome bioarray (http://www.codelink bioarrays.com/) that is a 3-D aqueous gel 
matrix slide surface with 30-base oligonucleotide probes. This 3-D gel matrix provides an 
aqueous environment that allows an optimal interaction between probe and target and 




Fig. 3. Representation of the different steps necessary for the microarray analysis, starting 
from NiV infection of HUVEC cultures up to the analysis of microarrays. 
Codelink human whole genome bioarray comprises approximately 55,000 30-mer probes on 
a single array based on the NCBI/Unigene database that permits the expression analysis of 
57,347 transcripts and ESTs. In addition to these 55,000 probes, Codelink human whole 
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genome bioarrays also contain one set of 100 housekeeping genes, 108 positive controls and 
384 negative controls (bacterial genes). Hybridization, wash and revelation were performed 
using Codelink Expression Assay reagent kits. Then, chips were scanned using an Axon 
Genepix 4000B Scanner. Data extraction and raw data normalization were performed using 
the CodeLink Gene Expression Analysis v4.0 software. Normalization was performed by the 
global method. The threshold was calculated using the normalized signal intensity of the 
negative controls supplemented by 3 times the standard deviation. Spots with signal 
intensity below this threshold are referred to as “absent”. Finally, data are converted to the 
excel format and data analysis is performed by using the Gene Spring v7.0 software from 
Agilent. 
2.3 Microarray data analysis 
The effect of NiV on the modulation of the genes expression was determined by 
permutation analysis and we considered as pertinent a minimal fold change (FC) of 1,3. 
Among the 55,000 targeted genes, 1076 genes were found to be differentially expressed in 
NiV-infected cells in comparison to non infected cells, including 807 up-regulated genes (1.3 
≤ FC ≤ 23) and 269 down-regulated (-46 ≤ FC ≤ -1.3) genes. These 807 up-regulated genes 
were then classified according to their Gene Ontology (GO) biological processes and their 
GO molecular functions. This system of clustering takes into account not only the number of 
genes but also the importance of the modulations in each function. Most of the cellular 
functions were modified after NiV infection (Fig. 4A). This could be explained by the 
modulation of some key genes involved in the large majority of the known functions. The 
most importantly modulated functions were those belonging to “Immune Response” with 
37 differentially regulated genes (Table 1A) and to “Organism Abnormalities and Injuries” 
(22 genes), two functions that are usually altered in case of productive viral infection. 
Surprisingly, this analysis also revealed changes in the “neurological diseases” function (15 
genes) and “nervous dysfunctions” (5 genes). This result could be correlated with the strong 
involvement of the endothelial cell-induced inflammatory reaction in the development of 
the encephalitis, as described in the introduction. 
To refine the significance of these up-regulated genes, we next investigated the biological 
functions and interactions of these genes using Ingenuity Pathway Analysis (IPA) 
software. IPA allows genes that are differentially expressed to be placed in a physiological 
and biochemical context by grouping them according to canonical pathway and biological 
network with a statistical probability of validity, based on number of genes being 
differentially expressed in the respective pathway. This IPA analysis allowed us to 
identify that the most significantly modulated canonical pathway is the “interferon 
signaling” pathway (p=0,01) (Fig. 4 B). The majority of the top 15 up-regulated genes are 
related to the Interferon pathway (Table 1B). The involvement of the Interferon pathway 
has been proposed in the development of the other types of vasculitis, including the post-
operative vasculitis (Abe et al., 2008). Four other canonical pathways were significantly 
found modified during the infection by NiV: “Antigen presentation”, “Integrin 
signaling”, “Protein Ubiquitination” and “Nicotinate and Nicotinamide Metabolism” 
pathways. Finally, IPA allowed us to demonstrate the existence of network of genes 
involved in the pathway of Gene expression, Cell Death, Connective tissue disorders (Fig. 
5). Some of these gene, like TLR3 (Shaw et al., 2005) and CXCL10 (Lo et al., 2010), have 
been already shown to be associated to NiV infection, while the role of other genes rests to 
be demonstrated. 
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Table 1. Genes differentially expressed during NiV infection in the Immune Response (A), 
Interferon pathway (B), protein ubiquitination pathway (C). 
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Fig. 4. Impact of NiV infection on biological functions (A) and canonical pathways (B), 
determined using Ingenuity Pathway Analysis. 
 
 
Score Focus Genes Top Functions 
56 35 
Gene Expression, Cell Death, Connective Tissue 
Disorders 
24 21 
Organismal Injury and Abnormalities, Cellular 
Movement, Hematological System Development and 
Function 
16 16 
Cellular Movement, Hematological System Development 
and Function, Immune Response 
16 16 
Immune Response, Cell-To-Cell Signaling and 
Interaction, Hematological System Development and 
Function 
16 16 
Cell Death, Carbohydrate Metabolism, Cellular 
Assembly and Organization 
Table 2. Putative Networks with high score, identified by Ingenuity Pathway Analysis 
In addition, this IP analysis revealed that the 2 top putative networks with high score (> 20) 
were strongly associated with the “Connective Tissue Disorders” and the “Hematological 
System Development and Function” (Table 2). As microvascular basal lamina plays a critical 
role in brain injury (Wang & Shuaib, 2007), the loss of basal lamina components may reflect 
the degradation of proteins by proteolitic enzymes. 
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Fig. 5. Gene network identified in NiV infected HUVEC, compared to mock infected 
controls, reveals involvement of different genes within the pathways of Gene expression, 
Cell Death and Connective tissue disorders.  
2.4 Validation of genes by quantitative real time PCR 
To validate data obtained by microarray, we compared mRNA levels of several highest 
upregulated genes involved in the Immune response, between NiV infected and uninfected 
cells. These genes included Mx1, OAS1, CXCL10, CXCL11, PSMB9 (also known as LMP2) 
and RIGB. Total RNA were extracted 8 hours post-infection. Reverse transcriptions were 
performed on 0,5 µg of total RNA using the iScript cDNA synthesis kit (Bio-Rad) and run in 
Biometra® T-GRADIENT PCR devise. Obtained cDNAs were diluted 1/10. Quantitative 
PCR was performed using Platinum® SYBR® Green qPCR SuperMix-UDG with ROX kit 
(Invitrogen™). qPCR was run on the ABI 7000 PCR system (Applied biosystems) using the 
following protocol: 95°C 5’, and 40 cycles of 95°C 15’’, 60°C 1’, followed by a melting curve 
up to 95°C at 0.8°C intervals. All samples were run in duplicate and results were analyzed 
using ABI Prism 7000 SDS software available in the genetic analysis platform (IFR128 
BioSciences Lyon-Gerland). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used as housekeeping gene for viral mRNA quantification and normalization. GAPDH and 
standard references for the corresponding genes were included in each run to standardize 
results in respect to RNA integrity, loaded quantity and inter-PCR variations. Primers used 
were design using Beacon 7.0 software, and validated for their efficacy close to 100%: RiGB 
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for: ATCATCAGCAGTGAGAAC, RiGB rev: GAACTCTTCGGCATTCTT, LMP2 for: 
GGTCAGGTATATGGAACC, LMP2 rev: CATTGCCCAAGATGACTC, GAPDH for: 
CACCCACTCCTCCACCTTTGAC, GAPDH rev: GTCCACCACCCTGTTGCTGTAG. The 
relative expression represents the ratio of the number of copy of mRNA of interest versus 
mRNA of GAPDH. All calculations were done using the 2∆∆CT model of (Pfaffl, 2001) and 
experiments were performed according to the MIQE guideline (Bustin et al., 2009). 
 
 
Fig. 6. Example of genes used for the validation of the microarray data. Results obtained 
from the microarray are shown on the left, whereas RT-qPCR data for the same gene are 
shown on the right. 
2.5 Focus on some genes of interest 
Among the cellular pathways activated during the NiV infection, we have particularly 
focused our attention to the interferon related genes. We have observed that similarly to the 
other Paramyxoviruses, NiV strongly activates the immune response through the canonical 
interferon signaling pathway. An over expression of some interferon related genes is known 
to lead to the activation of several genes related to the proteasome and the ubiquitination 
pathway. Those genes are involved in loading and expression of the CMH class 1 at the cell 
surface. In fact, any imbalances in this system can lead to a strong deregulation, resulting in 
inflammation that could not be controlled by host homeostatic mecahanisms (example: 
lupus erythematous, (Baechler et al., 2004). TAP1/2 and LMP2 (PSMB9) are the major 
proteins involved in this system, and both were shown to be up-regulated during NiV 
infection of endothelial cells (Table 1). The expression of those proteins is regulated by 
Interferon related proteins called Signal Transducer and Activator of Transcription 1ǂ 
(STAT1ǂ) and Interferon Regulatory Factor 1 (IRF1) (Chatterjee-Kishore et al., 1998). In 
normal conditions, TAP1 and 2 are expressed at a basal level in cells, whereas LMP2 is not 
found (Wright et al., 1995). Our results show that NiV infection increases TAP1 expression 
without any changes in TAP2. Moreover, LMP2 was also induced. An imbalance in the 
expression of those proteins that are the major components of the immunoproteasome, are 
in certain cases responsible for important phenomena of autoimmunity leading to severe 
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damages on the endothelium, including systemic vasculitis in case of Lupus (Zimmer et al., 
1998) and may be therefore involved in the pathogenesis of NiV induced vasculitis.  
In addition, our results revealed NiV-induced up regulation of HERC5 (FC=5,37), which 
belongs to the E3 ubiquitin ligases family. This protein has been shown to be tightly 
controlled under inflammatory conditions in endothelial cells (Kroismayr et al., 2004). The 
critical role of Tumor necrosis factor ǂ, Interleukin 1ǃ and NF-KB was suggested in the 
regulation of this protein. Although we have observed an over expression of TNFSF13b in 
the NiV infected HUVEC, modulation of IL1ǃ or NF-KB was not found, suggesting another 
cascade of NiV-induced activation of HERC5.  
Virus infection is known to induce a specific chemokine production in infected cells. This 
chemokine response is often related to the detection of viral genomes by Toll like receptor 
(TLR) system. Depending on the combination of TLRs involved in this mechanism it will 
lead to a specific signature of expression. For example, the closely related Measles virus 
induces several chemokines CCL2, CCL3, CCL4, CCL5 and CXCL10 (Glass et al., 2003). 
Only CXCL10, CXCL11 and CCL8 were induced by NiV infection in HUVEC (Table 1), 
suggesting a high capacity of NiV to provoke an imbalance of cell signaling, leading to a 
miss regulation of inflammation. These results are in accord with demonstrated changes in 
cytokine production by endothelial cells (Lo et al., 2010). The strong involvement of 
Interferon related genes in the vasculitis has been described before, but the induction of the 
monocyte chemoattractant CCL8 remains unclear in the context of a viral infection. Indeed, 
very few viruses are inducing this protein (Glass et al., 2003). Nevertheless, CCL8 has been 
shown to be involved in many inflammatory diseases including rheumatoid arthritis 
(Galligan et al., 2007), (Ockinger et al., 2010) and Graft versus host diseases (Bouazzaoui et 
al., 2009). The functional importance of CC chemokine ligand genes has been demonstrated 
in experimental autoimmune encephalomyelitis and multiple sclerosis (Mahad et al., 2004), 
(Savarin-Vuaillat & Ransohoff 2007). CCL8 is overexpressed by astrocytes and microglia 
leading to the over recruitment of monocytes and macrophages to the lesions (Vyshkina et 
al., 2008). This result suggests the importance of regulation of CCL8 either at the genomic 
level or within the chemokine network, when the virus reaches the brain. 
Furthermore, within genes involved in the cellular movement function NiV induced the 
expression of ADAM 12 (FC=2,38). This protein is a metalloprotease proposed to function as 
a regulator of fusion of several cell types, including trophoblast and myoblast (Huppertz et 
al., 2006). This protein also modulates the cell fusion in giant cell tumors of long bones 
(Meng et al., 2005), by inducing actin cytoskeleton reorganization. This reorganization could 
be associated to the remodeling of actin induced by NiV binding to its receptor and 
consequent EFNB2 signaling. In addition to the capacity of ADAM12 to reorganize the 
extracellular matrix, its over expression in endothelial cells could be related not only to the 
syncytia formation but also to microvascular basal lamina damages. This phenomenon 
causes dismantlement of the endothelial wall structure (Wang & Shuaib, 2007). Such 
microvascular permeability in the brain could compromise the microcirculation by 
increasing the risk of ischemia and the exposure of this compartment to the immune system, 
leading thus to an important vascular and perivascular inflammation. 
3. Conclusions 
NiV is a highly lethal zoonotic pathogen that can cause important socio-economical and 
health problems. This virus induces a generalized vasculitis leading to the disruption of the 
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endothelial microvascular tissue in brain and inducing severe damages in the CNS. 
Micorarray analysis of NiV infected primary endothelial cells allowed us to obtain a global 
overview of the host cell responses to NiV early during the infection. This global approach 
revealed that NiV infection has an important impact in several pathways and functions that 
are directly related to the pathogenesis observed in patients and animals. The analysis 
revealed a high induction of the immune response through the important modulation of 
genes in the Interferon signaling pathway, Antigen presentation pathway and the Protein 
ubiquitination pathway. We focused our analysis on several highly induced genes which 
could be involved in the control of the vascular inflammation and disruption of 
endothelium, allowing the passage of the virus in the organs. The early NiV infection of 
endothelial cells importantly upregulated the chemokines TNFSF13B, CXCL10, CXCL11 and 
CCL8 that are involved in many processes of autoimmune diseases as well as proteins 
belonging to the ubiquitination pathway. More precisely, TAP1 and LMP2 were 
overexpressed during the infection. NiV-induced sustained inflammatory conditions and 
modified regulation of the immunoproteasome expression could lead to an imbalance of the 
MHC class 1 exposure at the surface of cells, inducing haemostatic disturbance during NiV 
infection. This study presents the first comprehensive analysis of global host transcriptional 
response to NiV infection. Obtained results shed new light to early stage of NiV 
pathogenesis and should help in understanding the host response to this virus and open 
perspectives for design of  treatment for this emerging lethal infectious disease. 
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